Background. In 2008, the empiric vancomycin dosing recommendation in children at our institution was changed from 40 to 60 mg/kg per day. Subsequently, an increased incidence of acute kidney injury (AKI) in patients receiving vancomycin was suspected. The objective of this study was to evaluate AKI in children receiving vancomycin and to determine risk factors for AKI development. Methods. Medical records of patients aged 30 days through 17 years who received vancomycin for at least 72 hours between January and December 2007 (40 mg/kg per day) and January and December 2010 (60 mg/kg per day) were reviewed. Patients with cystic fibrosis, an elevated baseline serum creatinine, or without a serum creatinine concentration obtained after receipt of vancomycin were excluded. Acute kidney injury was defined using adapted pediatric RIFLE criteria as an increase in serum creatinine from baseline of 50% or more. Results. Acute kidney injury occurred in 19.4%of the 859 children included, with no difference between the 2007 and 2010 periods (18.8% vs 20%, respectively; P =.636). Intensive care unit admission (odds ratio [OR], 1.86; 95% confidence interval [CI], 1.20-2.94) and an initial vancomycin trough concentration ≥15 mg/L (OR, 2.18; 95% CI, 1.21-3.92) were determined to be significantly associated with AKI. Conclusions. These results suggest an initial vancomycin serum trough concentration of ≥15 mg/L and intensive care unit admission are predictors of AKI in this pediatric population. © The Author 2013. Published by Oxford University Press on behalf of the Pediatric Infectious Diseases Society. All rights reserved.
CITATION STYLE
Knoderer, C. A., Nichols, K. R., Lyon, K. C., Veverka, M. M., & Wilson, A. C. (2014). Are elevated vancomycin serum trough concentrations achievedwithin the first 7 days of therapy associatedwith acute kidney injury in children? Journal of the Pediatric Infectious Diseases Society, 3(2), 127–131. https://doi.org/10.1093/jpids/pit076
Mendeley helps you to discover research relevant for your work.